176
Views
21
CrossRef citations to date
0
Altmetric
Original Article

Topiramate-induced Bilateral Anterior Uveitis Associated with Hypopyon Formation

, MD, & , MD
Pages 86-88 | Received 10 May 2010, Accepted 10 Sep 2010, Published online: 31 Oct 2010
 

Abstract

Purpose: To report a rare case of bilateral anterior uveitis with hypopyon formation following systemic topiramate use.

Materials and Methods: A 40-year-old woman with migraine headache who was under topiramate treatment referred with bilateral ocular pain and visual blurring. Physical examination disclosed shallow anterior chamber and high intraocular pressure in both eyes. Following discontinuation of topiramate a severe bilateral anterior uveitis with posterior synechiae and hypopyon developed.

Results: Ocular inflammation resolved with systemic and topical steroid. Because of severe cataract and synechiae formation she underwent phacoemulsification/posterior chamber intraocular lens implantation and visual acuity of both eyes improved to 20/25.

Conclusion: Topiramate should be added to the list of drugs that may cause anterior uveitis and hypopyon formation.

ACKNOWLEDGMENTS

This study was supported by the Ophthalmic Research Center of Shahid Beheshti University (MC), Tehran, Iran.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.